Moreover, many biomarkers such as cerebrospinal fluid (CSF) Aβ1-42 and tau proteins have emerged as intermediate phenotype approaches in genetic analyses of risk for us to explore the association between genetic variation and process of AD. This evidence concerns the gene MAPT and Alzheimer disease.